The surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in the European Union/European Economic Area (EU/EEA) is essential for detecting emerging and increasing antimicrobial resistance. Since 2009, this surveillance has been co-ordinated by the European Centre for Disease Prevention and Control (ECDC). The quality-assured data produced can be used to inform treatment guidelines.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 30 August - 5 Sep 2020 and includes updates on COVID-19, Ebola virus disease, MERS, Dengue, CCHF, West Nile Virus.
Approximately four in five people living with hepatitis B and three out of four people with hepatitis C infection across the European Union and European Economic Area (EU/EEA) and the UK have not yet been diagnosed. This is a major obstacle on the way towards the Sustainable Development Goal (SDG) for health in 2030 as highlighted by ECDC on occasion of World Hepatitis Day.
The first report monitoring the progress towards the elimination of hepatitis B and C across European Union (EU) and European Economic Area (EEA) countries has been published by ECDC.
The surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in the European Union/European Economic Area (EU/EEA) has been co-ordinated by the European Centre for Disease Prevention and Control (ECDC) since 2009. This surveillance is essential for detecting emerging and increasing antimicrobial resistance and making quality-assured data available to inform treatment guidelines.